pfizer oral glp 1 Danuglipron: An GLP-1R Agonist Competing with Peptide Injectables for Diabetes and Obesity FDA approves Foundayo, an oral

Los resultados mostraron que las muertes por enfermedades cardiovasculares se redujeron en gran medida en los pacientes que se administraron liraglutida en comparacin con los que no lo hicieron

Glucagon-like peptide-1 receptor agonists, but not dipeptidyl peptidase-4 inhibitors, reduce alcohol intake

Unlike traditional oral supplements that rely on the digestive system, PatchMDs transdermal patches deliver nutrients directly through the skin, avoiding potential gastrointestinal discomfort and absorption issues

39 Conventional risk factors for diabetic gastroparesis include a long duration of diabetes, presence of other microvascular complications, smoking, obesity and female sex

For a precise reading, a DEXA or bioimpedance scan is the gold standard but this flags your risk in seconds, for free

Select patients based on mechanism: insulin resistance, compulsivity, cravings